2 The production of envelope glycoproteins (Envs) for use as HIV vaccines is challenging.
134 accumulation in cell culture medium ( Fig. 3C ), we found that rgp120 production 135 increased after the addition of sodium butyrate at day six with the rate of accumulation 136 stabilizing between 10-14 days of cell culture. During this period, rgp120 became the 137 major protein secreted into the cell culture medium.
2.3 Growth characteristics of MGAT1 -CHO cells expressing A244_N332-rgp120
139
Several experiments were performed to characterize the growth characteristics of 140 MGAT1 -CHO cells expressing A244_N332-rgp120. The initial 125-500mg/L yield, was 141 obtained using culture conditions primarily designed for transient expression of 142 recombinant proteins following electroporation. Data is shown in Figure 4A -C from 143 triplicate cultures of 5F MGAT1 -CHO (600 mL cultures grown in 1.6 L shake flasks) for 144 a 13-day culture period. Cells were grown at 37 o C until they reached late log growth 145 phase (six days) then sodium butyrate was added to enhance protein expression and 146 the temperature was shifted to 32 o C for the remainder of the experiment (Fig. 4A ). The 147 cell viability ranged from 90-100% for the first 8 days of culture and then steadily 148 declined. In contrast the cumulative amount of rgp120 in the cell culture medium 149 continued to accumulate over the entire 13-day culture (Fig. 4C ) reaching a maximum of 150 800 mg/L by harvest. Figure 4 panels D-F show a similar batch fed experiment to test 151 the effect of different feed additives on protein production by the 5F MGAT1 -CHO line.
152 Five (duplicate) batch fed culture of the 5F MGAT1 -CHO isolate were grown in shake 156 support protein expression in CHO cells, reviewed in (63). The cells were again grown 157 at 37 o C until they reached late log growth phase (six days) with a viable cell density 158 approaching 1x10 7 cells per ml, adding Sodium butyrate (1mM) and shifting the 159 temperature 32 o C for the remainder of the experiment (Fig. 4D ). There were small 160 differences in cell growth and viability ( Fig. 4D and 4F) and productivity with the different 161 peptone hydrolysate additives which might be further explored prior to large scale 162 production, however, all supported 1g/L production of rgp120 at harvest ( Fig. 4F ).
163 These studies demonstrate that the 5F MGAT1 -CHO cell line expressing A244_N332-164 rgp120 can be grown to high cell densities and is productive for up to 12-14 days in 165 culture. It is likely that media optimization and a regulated bioreactor system can 166 improve cell viability, cell densities, and rgp120 expression 
205
For purposes of comparison, rgp120 binding to the virus entry inhibitor CD4-IgG 206 served as a positive control. We first examined rgp120 binding by the prototypic glycan 207 dependent bNAb PG9, that binds the core mannose residues of two glycans at position 208 N160 and either N156 or N173 within the V1V2 domain (18). The glycan at N160 was 209 initially identified as Man5 in the context of a V1V2 scaffold structure (66) but recent 210 reports suggest that PG9 is more tolerant of heterogeneity than initially thought (14, 67).
211 Consistent with the hypothesis that a complex glycan at position N160 might interfere 212 with PG9 binding, glycan mapping of CHO-S produced monomeric rgp120 revealed 213 complex glycans at positions N156 and N160 (68, 69). We observe a quantitative 214 difference ( Fig. 6A ) between the binding affinity of rgp120 A224-N332 produced in 215 MGAT1 -CHO cells as measured by EC50 (1.33 nM) for PG9, when compared to the 216 RV144 antigen, rgp120 A224, produced in CHO S cells (no binding plateau). This result 217 is in concordance with data from previous transient transfection studies (57, 58) .
218 Binding of bN-mAbs to protein produced in the 5F MGAT1 -CHO cell line was 219 indistinguishable to protein produced by transient transfection in MGAT1 -CHO cells.
220
We examined rgp120 binding to four bN-mAbs from two different families that are 221 known to recognize glycan dependent epitopes in the stem of the V3 domain. PGT126
222 and PGT128 bN-mAbs are both members of the PGT128 family, and were derived from 223 a common ancestral immunoglobulin VH gene (17). The bN-mAb 10-1074 is a member 224 of the PGT121 family, and both antibodies were derived from a common ancestral 225 immunoglobulin VH region gene distinct from the PGT128 family (13, 17). We observed 226 significantly improved binding to members of the PGT128 family to MGAT1 -CHO-S 227 produced A244_N332 rgp120 compared to the CHO-S A244 protein; however the 228 magnitude of the difference was much greater for PGT126 compared to PGT128 ( Fig.   229 6B and 6C ). Improved PGT128 family binding is consistent with enrichment of N332
230 with Man5-9 glycans as PGT126/128 epitopes bind core residues of high mannose at 231 positions N301 and N332, or N295 and N334 ( 15, 17, 19, 20) . Mass spectroscopy of 232 virion-derived gp120 has shown that asparagine at position 332 is occupied by Man5-9
233 glycans with Man8-9 dominating (32). However on CHO-S derived rgp120, high 234 mannose is dominant but not exclusive (68, 69). Our binding data suggests that the 235 PGT126 epitope is more sensitive to occlusion by proximal processed glycans than 236 PGT128.
237
Members of the PGT121 family (PGT121 and 10-10-74) differed considerably in 238 their ability to bind MGAT1 -A244_N332 and CHO-S A244 rgp120 ( Fig. 5D and 5E).
239 PGT121 is different from all of the other glycan dependent bN-mAbs tested in that it 240 accommodates either a sialylated or high mannose glycan at positions N332 or N334, 241 and a sialyated glycan at position N137, whereas 10-1074 is N332 high-mannose
242 restricted (13, 17). We observed significantly improved binding of 10-1074 to 243 A244_N332 rgp120 produced in the MGAT1 -CHO cell line, and poor binding of 244 PGT121. PGT121 did not bind rgp120 made in CHO-S cells. In control experiments, we 245 found that all of the proteins tested bound to VRC01 bN-mAb. We noted a small but 246 consistent higher maximal binding of VRC01 to proteins produced in the MGAT1 -CHO 247 cell line compared to the CHO-S cell line (Fig. 6F) . This difference was also previously 248 reported (57). VRC01 is an anti-CD4 binding site antibody with low affinity for glycan in 13 249 glycan-array assay (65). Glycans N197, N276 and N262 or N263 overlap with the 250 binding site, and an N276 mannose core /VRC01 light chain contact was recently 251 identified by (70). All proteins tested bound comparably to CD4-IgG regardless of the 252 expression system (Fig. 6G) , indicating that the CD4 binding site was properly folded 253 and that the concentrations of the individual proteins were identical. Similarly, all of the 254 Env proteins captured with the 34.1 Mab used in this experiment, bound comparably to 255 the PB94 polyclonal rabbit sera (Fig. 6H ). Thus, there was no significant difference in 256 the concentration or coating efficiencies of the proteins used for the binding studies. 294 The addition of these glycan dependent epitopes represents a significant improvement 15 295 in the antigenic structure of A244-rgp120 and might improve the level of efficacy that 296 can be obtained from an RV144-like immunization regimen.
297
Prior to the development of the MGAT1 -CHO 3.4F10 cell line there was no 298 practical means by which recombinant Env proteins enriched for high mannose glycans
299 could be produced at large scale for HIV vaccine production. In these studies, we 300 demonstrated that CHO cell lines expressing up to 1g/L of rgp120 that are potential 301 candidates for vaccine antigen production, can be produced within 2-3 months. In 302 contrast, the CHO cell line used to produce A244-rgp120 used in the RV144 trial 303 produced only 20 mg/L and took more than 18 months to develop (Berman, P.W., 304 personal communication).
305
Previous studies have shown that early intermediates in the N-linked 306 glycosylation pathway (Man5 or Man9) are essential components of many epitopes 307 recognized by bN-mAbs (11-16, 18, 19, 20) . Additionally, we now know that HIV virion-308 associated Env proteins are enriched for these early intermediates in the glycosylation 309 pathway (20, 31, 50, 71). The A244_N332-rgp120 protein produced in the 5F MGAT1 -310 CHO cell line possesses multiple glycan dependent epitopes recognized by bN-mAbs 311 and appears to possess a glycan structure that more closely resembles authentic HIV 312 Env proteins compared to Env proteins produced in normal CHO cells. We hypothesize 313 that this "glycan optimized" immunogen produced in the 5F MGAT1 -CHO cell line 314 might increase the potential level of protection documented in the RV144 trial from 315 31.2% (P=0.04) to the efficacy level of 50% or more thought to be required for 316 regulatory approval and clinical deployment (72).
317
These studies demonstrate that the MGAT1 -CHO cell line is a suitable substrate 318 for stable cell line development (57). The 5F MGAT1 -CHO line can be grown at high 319 densities (2x10 7 cells/mL) in serum free media for the length of time (8-10 days) 320 consistent with modern manufacturing methods intended for the production of HIV 321 vaccine immunogens. The success in cell line isolation was greatly enhanced by the 322 use of robotic selection. The MaxCyte STX electroporation system achieved 323 transfection efficiencies of greater than 80% with linearized plasmid. Another key step 324 in the robotic screening strategy was the need to develop an imaging reagent that 325 formed "halos" around rgp120 transfected cells. We found that the best "halos" resulting 326 from the formation of immune-precipitin bands in semi-solid methylcellulose media were 327 only obtained with fluorescently labeled polyclonal antibodies. Although previous 328 anecdotal reports suggested that mixtures of fluorescently labeled monoclonal 329 antibodies could form the immune-precipitin bands required for robotic selection, we 330 were unable to confirm these reports. Finally, we attempted to see if the robotic 331 selection could overcome the need for time-consuming gene amplification experiments 332 (via methotrexate or methionine sulphoximine), and we found that directly screening 333 approximately 40,000 clones in a single ClonePix2 experiment was adequate to isolate 334 a cell line that produced approximately 1g/L of rgp120 with no gene amplification.
335 Studies are in progress to determine whether the high expression levels found in this 336 study results from the selection of cell lines with high levels of amplified genes or from 337 integration of the HIV transgene into transcriptionally active regions of chromatin.
338
The new technology outlined here should allow for the rapid production and 339 testing of multiple new Env based vaccine concepts that have not previously been 340 tested for lack of a fast and cost effective manufacturing process. Such concepts 341 include multivalent rgp120 vaccines (73), guided immunization vaccine strategies (73-342 77), and Env proteins optimized for the binding of inferred ancestral forms of bN-mAbs 343 (78-80). In summary, by combining recent developments in transfection technology, 344 robotic selection, and gene editing, we have developed a novel method for the 345 production of recombinant Env proteins has the potential to improve the potency, standard laboratory conditions were selected in less than two months. Production was subsequently increased to levels of g/L rgp120 production with minimal feed optimization.
